Silvia Foti

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Vanesa Gregorc, Silvia Novello, Chiara Lazzari et al. · The Lancet Oncology · 2014 · 158 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).

Matt D. Galsky, Gianluca Del Conte, Silvia Foti et al. · Journal of Clinical Oncology · 2022 · 85 citations

Medicine, Oncology, Pharmacology +17

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Margherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato et al. · European Journal of Cancer · 2024 · 44 citations · Full text

Medicine, Oncology, Pharmacology +13

Skin DVHs predict cutaneous toxicity in Head and Neck Cancer patients treated with Tomotherapy

Martina Mori, G.M. Cattaneo, I. Dell’Oca et al. · Physica Medica · 2019 · 30 citations

Medicine, Oncology, Radiation Oncology +14

Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).

Chiara Lazzari, Silvia Novello, Sandro Barni et al. · Journal of Clinical Oncology · 2013 · 24 citations

Medicine, Oncology, Pharmacology +12